Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Anavex Life Sciences Corp AVXL

Healthcare Biotechnology
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of... see more

Recent & Breaking News (NDAQ:AVXL)

Anavex Receives Regulatory Approval to Initiate Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS for Alzheimer's Disease

GlobeNewswire November 3, 2014

Institutional Investor Lincoln Park Capital Increases Ownership in Anavex, Pays Over 25% Premium to Market

GlobeNewswire October 27, 2014

Anavex Supports Alzheimer's Foundation of America's 3rd Annual Concepts in Care Educational Conference

GlobeNewswire September 8, 2014

Anavex to Present at Rodman & Renshaw 16th Annual Global Investment Conference

GlobeNewswire September 3, 2014

Anavex Selects The Alfred Hospital in Melbourne, Australia as Lead Site for Phase 2a Alzheimer's Clinical Trial

GlobeNewswire August 26, 2014

Anavex Reports That Antidepressant Fluvoxamine Reduces Stress Through Sigma-1 Receptor

GlobeNewswire August 19, 2014

Anavex Reports Fiscal Third Quarter 2014 Financial Results

GlobeNewswire August 13, 2014

Anavex Appoints Experienced Pharma Executive as Vice President of Clinical Operations

GlobeNewswire August 7, 2014

Anavex Achieves Key Milestone as it Secures cGMP Manufacturing for Drug Candidate Trial Supplies

GlobeNewswire July 21, 2014

ANAVEX 3-71 Highly Effective and Disease-Modifying Against All Major Alzheimer's Hallmarks in Preclinical Disease Model

GlobeNewswire July 14, 2014

Anavex Announces Report Expanding Opportunity for Therapeutic Application of Anavex Compounds

GlobeNewswire June 30, 2014

Anavex Awarded New U.S. Patent

GlobeNewswire June 4, 2014

Anavex Appoints Dr. Abraham Fisher to Scientific Advisory Board

GlobeNewswire May 28, 2014

Anavex Reports That New Data Confirms Calcium Target Over-Expression May be Involved in Causing Alzheimer's Disease

GlobeNewswire May 22, 2014

Anavex Provides Business Update Including Clinical Trial Plans for ANAVEX PLUS in Alzheimer's Disease

GlobeNewswire May 15, 2014

Anavex Strengthens Scientific Advisory Board With Clinical Trial Expert

GlobeNewswire May 12, 2014

Anavex Appoints Senior Healthcare and Pharmaceutical Executives to Board of Directors

GlobeNewswire May 8, 2014

Anavex Encouraged by Scientific Data Confirming Sigma-1 Receptor Agonist is Potentially Disease-Modifying in Parkinson's Disease

GlobeNewswire April 29, 2014

Anavex Strengthens Alzheimer's Pipeline, Obtains Exclusive Worldwide Rights to Intellectual Property

GlobeNewswire March 31, 2014

Anavex Reports Predicted Clinical Effect of Both ANAVEX 2-73 and ANAVEX PLUS in a Humanized Cortical Cognitive Model for Alzheimer's Disease

GlobeNewswire March 27, 2014